Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 968-981

  Kehne, John H ^a   Baron, Bruce M ^a   Carr, Albert A ^a   Chaney, Stephen F ^a   Elands, Jack ^a   Feldman, Daniel J ^b   Frank, Robert A ^b   Van Giersbergen, Paul L M ^a   Mccloskey, Timothy C ^a   Johnson, Michael P ^a   Mccarty, Deborah R ^a   Poirot, Matthieu ^a   Senyah, Yaw ^a   Siegel, Barry W ^a   Widmaier, Corinne ^a  

^a SANOFI   (France)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPEROZIDE; CLOZAPINE; HALOPERIDOL; MESULERGINE; RISPERIDONE; RITANSERIN; SEROTONIN 2A ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LIGAND BINDING; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN; FLUOROBENZENES; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES; RATS; SEROTONIN ANTAGONISTS;

EID: 0030431577     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. 2 antagonist. Drug Dev. Res. 15: 61-73, 1988.
2. AXELSSON, R., NILSSON, A., CHRISTENSSON, E. AND BJORK, A.: Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist. Psychopharmacology 104: 287-292, 1991.
3. BARNETT, A., MCQUADE, H. D. AND TEDFORD, C.: Highlights of D1 dopamine receptor antagonist research. Neurochem. Int. 20(suppl.): 119S-122S, 1992.
4. BERRIDGE, M. J., DOWNES, P. AND HANLEY, M. R.: Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem, J. 206: 587-595, 1982.
5. BORISON, R. L.: Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J. Clin. Psychopharmacol. 15: 24S-29S, 1995.
6. BREIER, A.: Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Res. 14: 187-202, 1995.
7. BURCHER, E., BUCK, S. H., LOVENBERG, W. AND O'DONOHUE, T.: Characterization and autoradiographic localization of multiple tachydinin binding sites in gastrointestinal tract and bladder. J. Pharmacol. Exp. Ther 236: 819-831, 1986.
8. 2 receptor antagonist MDL 100,907 attenuates the psychomotor stimulation induced by enhanced dopaminergic or reduced glutamatergic/muscarinic neurotransmission: Implications for psychosis. J. Neural Trans. [Gen Sect] 100: 225-237, 1995.
9. CARR, A. A.: The design and synthesis of 4-pipendinyl ketones and carbinols as selective receptor modulators: An approach to preferred drug candidates. American Chemical Society Award for Creative Invention, presented at the 205th American Chemical Society National Meeting, Denver, CO, 1993.
10. 2 receptors. International Congress on Schizophrenia Research, Tucson, AR, 1991.
11. CHIPKIN, R. D., IORIO, L. C., COFFIN, V. L., MCQUADE, R D., BERGER, J. G. AND BARNETT, A.: Pharmacological profile of SCH 39166: A dopamine D1 selective benzonaphtazepine with potential antipsychotic activity. J. Pharmacol. Exp. Ther. 247: 1093-1102, 1988.
12. CHOUINARD, G.: Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicenter Risperidone Study. J. Clin. Psychopharmacol. 15: 36S-44S, 1995.
13. CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MACEWAN, G. W., LABELLE, A., BEAUCLAIR, L. AND ARNOTT, W.: A Canadian multicenter placebo-controlled study of fixed doses risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13: 25-40, 1993.
14. CHRISTENSSON, E. AND BJORK, A.: Amperozide: A new pharmacological approach in the treatment of schizophrenia. Pharmacol. Toxicol. Suppl. 1: 5-7, 1990.
15. COLPAERT, F. C., LENAERTS, F. M., NIEMEGEERS, C. J. E. AND JANSSEN, P. A. J.: A critical study on Ro 4-1284 antagonism in mice. Arch. Int. Pharmacodyn. Ther. 215: 40-90, 1975.
16. 1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology 121: 323-327, 1995.
17. 3H]muscimol to subcellular particles of neuronal primary cultures and whole brains. J. Neurochem. 34: 216-218, 1980.
18. DEN BOER, J. A., VAN MEGEN, J. J. G. M., FLEISCHHACKER, W. W., LOUWERENS, J. W., SLAAP, B. R., WESTENBERG, H. G. M., BURROWS, G. D. AND SRIVASTAVA, O. N.: Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 121: 317-322, 1995.
19. 2 receptors. Drug Develop. Res. 13: 29-43, 1988.
20. 2/1C antagonist, and negative symptoms in schizophrenia: A placebo-controlled double-blind trial. Br. J. Psychiatry 163: 451-455, 1993.
21. EDDY, N. B. AND LEIMBACH, D. J.: Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines. J. Pharmacol. Exp. Ther. 107: 385-393, 1953.
22. ELLIS, K. O. AND CARPENTER, J. F.: A comparative study of Dantrolene sodium and other skeletal muscle relaxants with the straub tail mouse. Neuropharmacology 13: 211-214, 1974.
23. ERLANDER, M. G., LOVENBERG, T. W , BARON, B. M., DELECEA, L., DANIELSON, P. E., RACKE, M., SLONE, A. L., SIEGEL, B. W., FOYE, P. E., CANNON, K., BURNS, J. E. AND SUTCLIFFE, J. G.: Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc. Natl. Acad. Sci. USA 90: 3453-3456, 1993.
24. FINNEY, D. J.: Statistical method in biological assay, 3rd edition. MacMillan, New York, 1978.
25. FLEISCHHACKER W. W.: New drugs for the treatment of schizophrenic patients. Acta Psychiatr. Scand. 91(Suppl. 388): 24-30, 1995.
26. FREEDMAN, E. AND DALLOB, A.: Enhanced serotonin in receptor activity after chronic treatment with imipramine and amitriptyline. Commun. Psychopharmacol. 3: 89-92, 1979.
27. 2 receptor mediated excitation of interneurons in piriform cortex: Antagonism by atypical antipsychotic drugs. Neuroscience 58: 515-525, 1994.
28. GEWIRTZ, G. R., GORMAN, J. M., VOAVKA, J., MACALUSO, J., GRIBKOFF, G., TAYLOR, D. P. AND BORISON, R.: BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10: 37-40, 1994.
29. GIBSON, E. L., BARNFIELD, A. M. AND CURZON, G.: Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects Neuropharmacology 33: 457-465, 1994.
30. GOODMAN, L. S., GREWAL, M. S., BROWN, W. C. AND SWINYARD, E. A.: Comparison of maximal seizures evoked by pentylenetetrazol (Metrazol) and electroshock in mice, and their modification by anticonvulsants. J. Pharmacol. Exp. Ther. 108: 168-176, 1953.
31. 4 receptors in guinea pig and rat brain. Br J. Pharmacol. 109: 618-624, 1993.
32. GUSTAFSSON, B. AND CHRISTENSSON, E.: Amperozide - a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behavior. Pharmacol. Toxicol. 66(Suppl. 1: 12-17, 1990.
33. 2 antagonist, on parkinsonian rest tremor Curr. Ther. Res. 41: 298-300, 1987.
34. HIROI, N. AND WHITE, N.: Conditioned stereotypy: Behavioral specification of the UCS and pharmacological investigation of the neural change. Pharmacol. Biochem. Behav. 32: 249-258, 1989.
35. HOLCOMB, H. H., LAHTI, A. C., ZHAO, Z., MEDOFF, D., LANGE, N., DANNALS, R. F., WOODS, R. P. AND TAMMINGA, C. A.: Cerebral blood flow patterns induced by acute ketamine in man. Abstracts of Panels and Posters, American College of Neuropsychopharmacology, 33rd Annual Meeting, p. 151, San Juan, Puerto Rico, 1994.
36. 3H]sulpiride binding sites in the rat striatal membranes. Brain Res. 402: 331-338, 1987.
37. IORIO, L. C., COHEN, M. AND COFFIN, V. L.: Anticholinergic drugs potentiate dopamine D1 but not D2 antagonists on a conditioned avoidance task in rats. J. Pharmacol. Exp. Ther. 258: 118-123, 1991.
38. 2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc Nat. Acad. Sci. USA 87: 928-932, 1990.
39. JULIUS, D., LIVELLI, D., JESSELL, T. M. AND AXEL, R.: Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science (Wash., DC) 244: 1057-1062, 1989.
40. JULIUS, D., MACDERMOTT, A. B., AXEL, R. AND JESSEL, T. M.: Molecular characterization of a functional cDNA encoding the serotonin 1C receptor. Science (Wash., DC) 241: 558-564, 1988.
41. 125I-lysergic acid diethylamide binding to serotonin receptors in rat frontal cortex. J. Neurochem. 43: 601-606, 1984.
42. KANDEL, A.: Interactions of imipramine, amitriptyline and autonomic agents in reserpine-treated mice. Fed. Proc. 25: 385, 1966.
43. KANE, J. M., DUDLEY, M. W., SORENSEN, S. M. AND MILLER, F. P.: 2,4-Dihydro3H-1,2,4-triazole-3-thione as potential antidepressant agents. J. Med. Chem. 31: 1253-1258, 1988a.
44. KANE, J., HONIGFIELD, G., SINGER, J., MELTZER, H. AND THE CLOZARIL COLLABORATIVE STUDY GROUP: Clozapine for treatment resistant schizophrenia. Arch. Gen. Psychiatry 45: 789-796, 1988b.
45. KANE, J. M., STAEGER, M. A., DALTON, C. R., MILLER, F. P., DUDLEY, M. W., OGDEN, A. M., KEHNE, J. H., KETTELER, H. J., MCCLOSKEY, T. C., SENYAH, Y. CHMIELEWSKI, P. A. AND MILLER, J. A.: 5-Aryl-3-(alkylthio)-4H-1,2,4-triazoles as selective antagonists of strychnine-induced convulsions and potential antispastic agents. J. Med. Chem. 37: 125-132, 1994.
46. 1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121: 328-329, 1995.
47. 1-dopamine receptor antagonist SCH 39166 in acutely ill schizophrenic patients. Psychopharmacology 121: 309-316, 1995.
48. KARPER, L. P., GRILLON, C., CHARNEY, D. S. AND KRYSTAL, J. H.: The effect of ketamine on pre-pulse inhibition and attention. Abstracts of Panels and Posters, American College of Neuropsychopharmacology, 33rd Annual Meeting, p. 124, San Juan, Puerto Rico, 1994.
49. KEHNE, J. H , BARON, B. M., HARRISON, B. L., MCCLOSKEY, T. C., PALFREYMAN, M. G., POIROT, M., SALITURO, F. G., SIEGEL, B. W , SLONE, A. L., VAN GIERSBERGEN, P. L. M. AND WHITE, H. S.: MDL 100,458 and MDL 102,288: Two potent and selective glycine antagonists with different functional profiles. Eur. J. Pharmacol. 284: 109-118, 1995.
50. KEHNE, J. H., MCCLOSKEY, T. C., BARON, B. M., CHI, E. M., HARRISON, B. L., WHITTEN, J. P. AND PALFREYMAN, M. G.. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur. J. Pharmacol. 193: 283-292, 1991.
51. KEHNE, J. H., MILLER, F. P., KETTELER, H. J., BRAUN, D. L., SESYAK, Y., CHANEY, S. F., ABDALLAH, A., DUDLEY, M., OGDEN, A. M., PALFREYMAN, M. G. AND KANE, J. M.: MDL 27,531 selectively reverses strychnine induced seizures in mice. Br. J. Pharmacol. 106: 910-916, 1992
52. KEHNE, J. H., PADICH, R A., MCCLOSKEY, T. C., TAYLOR, V. L. AND SCHMIDT, C. J.: 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacology 1996, in press.
53. KEHNE, J. H., SANT, W. W. AND SORENSON, C. A.: The effects of radio-frequency lesions of the nucleus accumbens on D-amphetamine-induced locomotor and rearing behavior in rats. Psychopharmacology 75: 363-367, 1981.
54. 1C receptor antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology (Berl.) 107: 379-384, 1992.
55. 2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berl.) 114: 90-96, 1994.
56. KINNARD, W. J. AND CARR, C. J.: A preliminary procedure for the evaluation of central nervous system depressants. J. Pharmacol. Exp. Ther. 121: 354-361, 1957.
57. KLIESER, E., LEHMANN, E , KINZLER, E., WURTHMANN, C. AND HEINRICH, K.: Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with schizophrenia. J. Clin. Psychopharmacol. 15(Suppl. 1): 45S-51S, 1995.
58. 2 receptors. Psychopharmacology 112: S40-S54, 1993.
59. 2 receptor binding sites. Mol. Pharmacol. 21: 301-314, 1982.
60. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 11: 449-458, 1993a.
61. 1E-like rat and human 5-hydroxytryptamine receptor genes. Proc. Natl. Acad. Sci. USA 90: 2184-2188, 1993b.
62. LJUNGBERG, T. AND UNGERSTEDT, U.: Different behavioral patterns induced by apomorphine: Evidence that the method of administration determines the behavioural response to a drug. Eur. J. Pharmacol. 46: 41-50, 1977.
63. LJUNGBERG, T. AND UNGERSTEDT, U.: Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action. Psychopharmacol. 56: 239-247, 1978.
64. LJUNGBERG, T. AND UNGERSTEDT, U.: A rapid and simple behavioral screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol. Biochem Behav. 23: 479-485, 1985.
65. 2A antagonist. Eur. J. Pharmacol. 259: 137-141, 1994.
66. MATTHEWS, W. D. AND SMITH, C. D.: Pharmacological profile of a model for central serotonin receptor activation. Life Sci. 26: 1397-1403, 1980.
67. MATZ, R., RICK, W., THOMPSON, H. AND GERSHON, S.: Clozapine - A potential antipsychotic agent without extrapyramidal manifestations. Curr. Ther. Res. Clin. Exp. 16: 687-695, 1974.
68. 2A receptors. Eur. J. Pharmacol. 280: R9-R11, 1995.
69. MCQUADE, R. D., DUFFY, R. A., COFFIN, V. L. AND BARNETT, A.: In vivo binding to dopamine receptors: A correlate of potential antipsychotic activity. Eur. J. Pharmacol. 215: 29-34, 1992.
70. MEGENS, A. A. H. P., NIEMEGEERS, C. J. E. AND AWOUTERS, F. H. L.: Antipsychotic profile and side-effect liability of haloperidol, risperidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats. Drug Develop. Res. 26: 129-145, 1992.
71. MELTZER, H.: Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43: 587-604, 1991a.
72. MELTZER, H.: Studies of ondansetron in schizophrenia. Biol. Psychiatry 2: 891-893, 1991b.
73. MELTZER, H. Y.: The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J. Clin. Psychopharmacol. 15(Suppl. 1): 2S-3S, 1995.
74. MELTZER, H. Y., LEE, M. A. AND RANJAN, R.: Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr. Scand. 90(Suppl. 384): 95-101, 1994.
75. 2 pKi values. J. Pharmacol. Exp. Ther. 251: 238-246, 1989.
76. 2 receptor occupancy: Implications for antipsychotic action. Eur. J. Pharmacol. 216: 67-71, 1992.
77. 2 antagonist ritanserin. Psychopharmacol. Bull. 26: 373-376, 1990.
78. MINABE, Y., ASHBY, C. R. AND WANG, R. Y.: Effects produced by acute and chronic treatment with granisetron alone or in combination with haloperidol on midbrain dopamine neurons. Eur. Neuropsychopharmacol. 2: 127-133, 1992.
79. 3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons. Eur. J. Pharmacol. 209: 151-156, 1991.
80. MOLLER, H.-J.: The negative component in schizophrenia. Acta Psychiatr. Scand. 91(Suppl. 388): 11-14, 1995.
81. 2A antagonist. Behav. Brain Res. 73: 163-167, 1996.
82. 2 receptor: Structurally specific differentiation by ergoines and tryptamines. J. Pharmacol Exp. Ther. 265: 1272-1279, 1993.
83. NEWCOMER, J. W., FAUSTMAN, W. O., ZIPURSKY, R. B. AND CSERNANSKY, J. G.: Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial. Arch. Gen. Psychiatry 49: 751-752, 1992.
84. NIEMEGEERS, C. J. E.: Antagonism of reserpine-like activity. In Industrial Pharmacology, Vol. 2: Antidepressants, ed. by S. Fielding and H. Lal, pp. 73-98. Futura Publishing Co., Mt. Kisco, NY, 1975.
85. NOMIKOS, G. G., IURLO, M., ANDERSSON, J. L., KIMURA, K. AND SVENSSON, T. H.: Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology (Berl.) 115: 147-156, 1994.
86. ORTMAN, R., WALDMEIER, P. C., RADEKE, E., FELNER, A. AND DELINA-STULA, A.: The effects of 5-HTP uptake and MAO inhibitors on L-5-HTP-induced excitation in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 311: 185-192, 1980.
87. PADICH, R. A., MCCLOSKEY, T. C. AND KEHNE, J. H.: 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruptions of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology 1996, in press.
88. 3 mediated control of dopaminergic function. Psychopharmacology 112: S60-S67, 1993.
89. PEHEK, E. A., MELTZER, H. Y. AND YAMAMOTO, B. K.: The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur. J. Pharmacol. 240: 107-109, 1993.
90. PEROUTKA, S. J., U'PRITCHARD, D. C., GREENBERG, D. A. AND SNYDER, S. H.: Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. Neuropharmacology 16: 549-556, 1977.
91. PROTAIS, P., COSTENTIN, J. AND SCHWARTZ, J. C.: Climbing behavior induced by apomorphine in mice: A simple test for the study of dopamine receptors in striatum. Psychopharmacology 50: 1-6, 1976.
92. RANDRUP, A. AND MUNKVAD, I.: Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacology 11: 300-310, 1967.
93. 3 receptor antagonist zatosetron decrease the number of spontaneously active A10 dopamine neurons. Eur. J. Pharmacol. 205: 113-116 1991.
94. REYNTJENS, A., GELDERS, Y. G., HOPPENBROUWERS, J. A. AND VANDEN BUSSCHE, G.: Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Dev. Res. 8: 205-211, 1986.
95. 1C receptors. J. Pharmacol. Exp. Ther. 260: 1361-1365, 1992.
96. ROTH, B. L., CRAIGO, S. C., CHOUDHARRY, M. S., ULUER, A., MONSMA, F. J., SHEN, Y., MELTZER, H. Y. AND SIBLEY, D. R.: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268: 1403-1410, 1994.
97. 2 receptors in schizophrenia and antipsychotic activity. Int. Clin. Psychopharmacol. 8(Suppl. 2: 25-32, 1993.
98. 2 receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 223: 65-74, 1992.
99. 2A receptors in antipsychotic activity. Life Sci. 56: 2209-2222, 1995.
100. 1A agonist. J. Pharmacol. Exp. Ther. 273: 101-112, 1995.
101. SCHREIBER, R., BROCCO, M. AND MILLAN, M J.: Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and resperidone. Eur. J. Pharmacol. 264: 99-102, 1994.
102. SIPES, T. A. AND GEYER, M. A.: Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 38: 441-448, 1994.
103. 2 antagonist MDL 100,907 as a putative atypical antipsychotic: Behavioral, electrophysiological, and neurochemical studies. J. Pharmacol. Exp. Ther. 266: 1-8, 1993.
104. 3 receptor antagonist, on A9 and A10 dopamine neurons. Eur. J. Pharmacol. 163: 115-118, 1989.
105. 2 antagonist MDL 11,939 in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 15: 20-22, 1995.
106. 2 receptors as assessed by in vitro and in vivo binding. Eur. J. Pharmacol. 254: 73-81, 1994.
107. TAYLOR, D. P., EISON, M. S., MOON, S. L. AND YOCCA, F. D.: BMY-14802, a potential antipsychotic with selective affinity for sigma binding sites. In Schizophrenia Research Advances in Neuropsychiatry and Psychopharmacology, Vol. 1, ed. by C. A. Tamminga and S. C. Schulz, pp. 307-315, Raven Press, New York, 1991.
108. TOMAN, J. E. P., SWINYARD, E. A. AND GOODMAN, L. S.: Properties of maximal seizures and their alteration by anticonvulsant drugs and other agents. J. Neurophysiol. 9: 231-238, 1946.
109. 2 modulation of psychostimulant-induced facilitation of brain stimulation reward. Drug Develop. Res. 34: 297-305, 1995.
110. VON KNORRING, L. AND LINDSTROM, E.: Principal components and further possibilities with the PANSS. Acta Psychiatr. Scand. 91(Suppl. 388): 5-10, 1995.
111. WACHTEL, S. R. AND WHITE, F. J.: The effect of continuous and repeated administration of D1 dopamine receptor antagonist on midbrain dopamine neurons. Neurochem. Int. 20(suppl): 129S-133S, 1992.
112. 1D recognition sites: Radioligand binding studies in human, pig and calf brain membranes. Naunyn-Schmiedeberg's Arch. Pharmacol. 337: 595-601, 1988.
113. WANG, Z., HARACZ, J. L. AND REBEC, G. V.: BMY-14802. a sigma ligand and potential antipsychotic drug, reverses amphetamine-induced changes in neostriatal single-unit activity in freely moving rats. Synapse 12: 312-321, 1992.
114. WARBURTON, E. C., JOSEPH, M. H., FELDON, J., WEINER, I. AND GRAY, J. A.: Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: Implications for a possible antipsychotic action of ondansetron. Psychopharmacol. (Berl.) 14: 657-664, 1994.
115. WEINER, N.: Norepinephrine, epinephrine and the sympathorolmetic amines. In The Pharmacological Basis of Therapeutics, 6th edition, ed. by L. S. Goodman and A. Gilman, pp. 138-175, Macmillan, New York, 1980.
116. WIESEL, F. A., NORDSTRM, A. L., FARDE, L. AND ERIKSSON, B.: An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114: 31-38, 1994.
117. WHITTLE, B. A.: The use of changes in capillary permeability in mice to distinguish between narcotic and nonnarcotic analgesics. Br. J. Pharmacol. 22: 246-253, 1964.
118. WILLIAMS, P.: An open trial of ondansetron (GR38032F) in the treatment of acute schizophrenia. Schizophrenia Res. 3: 48, 1990.
119. WILLNER, P.: Animal models of depression. In. Behavioural Models in Psychopharmacology, pp. 91-125, Cambridge University Press, Cambridge, 1991.
120. YAMAMOTO, B. K. AND MELTZER, H. Y.: The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in. vivo. J. Pharmacol. Exp. Ther. 263: 180-185, 1992.
121. YOUNG, A. B. AND SNYDER, S. H.: Strychnine binding with glycine receptors of the central nervous system. Proc. Acad. Sci. USA 70: 2832-2836, 1973.